TUBERCULOSIS IN HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS.

Silvia F Costa, Jessica Ramos, Marjorie Vieira Batista
  • Silvia F Costa
    Infectious diseases of university of São Paulo, Brazil, Brazil
  • Jessica Ramos
    Department of Infectious Diseases, Medical School, University of São Paulo, Brazil., Brazil | silviacosta@usp.br
  • Marjorie Vieira Batista
    Department of Infectious Diseases, Medical School, University of São Paulo, Brazil., Brazil

Abstract

Description of tuberculosis (TB) among Hematopoietic Stem Cell Transplant (HSCT) recipients is scanty in the literature even in countries where TB is common. Most of reports of TB in HSCT patients were from ASIA, with TB incidence varying from 0.0014 (USA) to 16% (Pakistan). There are few reports of diagnosis of TB during the first two weeks after HSCT, most of cases described in the literature occurred after 90 days of HSCT, and the lung was the organ most often involved. The mortality varied from 0 to 50% and is higher among allogeneic HSCT. There is no consensus regarding the screening with tuberculin skin test or QuantiFERON-TB gold, and primary prophylaxis for latent TB, and whether in developing country with high prevalence of TB the epidemiologic query should be emphasized.

Keywords

Tuberculosis; Hemopoietic Stem Cell Transplantation

Full Text:

PDF
HTML
Submitted: 2014-06-13 09:56:01
Published: 2013-11-04 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
822

Views:
PDF
181
HTML
2167

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2016 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185